Gilead Sciences (GILD) Insider Mercier Sells $469K of Stock
Chief Communications and Corporate Affairs Officer Johanna Mercier executed a planned sale of 3,000 shares on October 15, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Johanna Mercier, Chief Comm & Corp Aff Officer at Gilead Sciences, Inc. ($GILD), sold 3,000 shares at an average price of $156.22, worth about $468,660, on October 15, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $GILD is down 0.8% to date (from the $157.37 close on Oct 15, 2026).
GILD
Gilead Sciences, Inc.
Key Points
- Gilead Sciences, Inc. Chief Comm & Corp Aff Officer Johanna Mercier sold 3,000 shares at a price of $156.22 per share on October 15, 2026, under a Rule 10b5-1 plan.
- After the trade, Johanna Mercier holds 113,684 $GILD shares, down 2.57% from before the trade.
- The transaction yielded a total value of $468,660, following an earlier sale by Mercier on September 15, 2026.
- Major institutional investors adjusted their positions recently, while the company prepares to report earnings on October 29, 2026.
Get $GILD trade alerts by text
We text you when insiders, Congress or big funds trade $GILD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Gilead Sciences, Inc. alert may contain errors. Disclosures
Inside Johanna Mercier's Gilead Sciences Trade
Johanna Mercier, Chief Comm & Corp Aff Officer at Gilead Sciences, Inc. (NasdaqGS: GILD), sold 3,000 shares of company stock on October 15, 2026. The shares were disposed of at an average price of $156.22, resulting in a total transaction value of $468,660. According to a Form 4 filed with the SEC, this transaction was executed under a pre-arranged Rule 10b5-1 plan. On the day of the trade, Gilead Sciences shares closed at $157.37.
This marks another transaction for Mercier, who previously sold 3,000 shares on September 15, 2026, for $432,646. Other top executives and board members have also transacted in recent months, including Chief Executive Officer Daniel Patrick O'Day and Chief Financial Officer Andrew D Dickinson.
Other Institutional Activity in Gilead Sciences
Blackrock Inc. grew its holdings by 2,832,477 shares, ending with 121,844,108 shares worth about $19,030,831,525. Vanguard Capital Management LLC added 435,543 shares for a 0.5% increase, holding 81,091,734 shares valued at $12,665,718,131. FMR, LLC reduced its stake by 5,033,287 shares or 7.0%, finishing with 66,870,816 shares worth $10,444,552,914. State Street Corporation lifted its position by 1,358,772 shares, a 2.3% boost that left it with 61,216,552 shares valued at $9,561,413,406. Capital World Investors trimmed its holdings by 293,103 shares, a 0.7% drop to 40,988,975 shares worth $6,402,068,105.
Gilead Sciences, Inc. Stock Down 1.0%
The stock recently traded around $155.84 as of October 16, 2026, sitting below its 52-week high of $160.51 and well above its 52-week low of $114.02. Shares are currently positioned above both their 50-day moving average of $146.33 and their 200-day moving average of $137.86.
Recent Earnings
Gilead Sciences reported trailing-twelve-month revenue of $30.46 billion alongside a negative basic earnings per share of $2.65. The company posted a net margin of -10.6% and a return on equity of -20.7%. Investors will look to the upcoming earnings release scheduled for October 29, 2026, for further financial updates.
Dividend
The company pays an annual dividend rate of $3.28 per share, giving it a dividend yield of 2.08% based on recent trading levels. The dividend payout ratio stands at 43.5%.
Insider Buying and Selling at Gilead Sciences, Inc.
Insider transactions over the prior months included Director Anthony Welters selling 18,000 shares on August 26, 2026, for $2,675,220. Chief Executive Officer Daniel Patrick O'Day sold 15,000 shares on September 1, 2026, for $2,229,592. Johanna Mercier sold 3,000 shares earlier on September 15, 2026, for $432,646, and Chief Financial Officer Andrew D Dickinson sold 3,000 shares on the same day at $145.29 per share for a total value of $435,870.
Analysts Set New Price Targets
Truist Securities maintained its Buy rating on October 7, 2026, raising its price target from $150.00 to $158.00. JP Morgan maintained an Overweight rating on October 7, 2026, lifting its target from $160.00 to $170.00. Morgan Stanley maintained an Overweight rating on October 7, 2026, adjusting its target from $165.00 down to $163.00. RBC Capital maintained a Sector Perform rating on October 8, 2026, moving its target from $123.00 to $126.00. Cantor Fitzgerald reiterated an Overweight rating on October 8, 2026, keeping its price target at $155.00. Overall, analysts maintain a consensus buy rating on the stock with a mean price target of $159.85 across 26 analyst opinions.
About Gilead Sciences
Gilead Sciences is a Foster City, California-based biopharmaceutical company that discovers, develops, and commercializes medicines for serious medical conditions in the United States and internationally. Its portfolio features treatments for HIV-1 infection such as Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo.
Bottom Line
Executive insider trades like this planned sale offer a look into internal positioning, though they often align with personal financial management rather than a shift in company outlook. Shareholders will watch the upcoming earnings report on October 29, 2026, for clues on operational momentum and profitability.
Related Filing Alerts
Source: Johanna Mercier's Form 4 filing on $GILD (Oct 15, 2026). Read the original filing: Form 4 filing on SEC EDGAR. Written by software, not financial advice. How we make alerts